Welcome to our dedicated page for MEDLINE news (Ticker: MDLN), a resource for investors and traders seeking the latest updates and insights on MEDLINE stock.
Medline Inc. (Nasdaq: MDLN) is a healthcare company focused on medical-surgical ("med-surg") products and supply chain solutions that serve hospitals, surgery centers, physician offices and post-acute care facilities. The Medline news page on Stock Titan highlights company announcements that explain how it operates as what it describes as the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products.
News related to Medline often centers on capital markets activity and corporate milestones, such as the public filing of its registration statement on Form S-1 with the U.S. Securities and Exchange Commission, the pricing of its upsized initial public offering of Class A common stock, and the closing of that upsized offering on the Nasdaq Global Select Market under the symbol MDLN. These updates provide context on Medline’s transition to being a publicly traded company and its use of offering proceeds for debt repayment, general corporate purposes and transactions with pre-IPO owners.
Investors and observers can also find Medline announcements about participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference. Such events can offer additional insight into how the company presents its med-surg product portfolio, supply chain capabilities and clinical solutions to the investment community.
This news page aggregates these types of press releases and corporate communications so readers can review Medline’s official statements over time. For anyone tracking MDLN, the page offers a focused view of the company’s own disclosures about its business focus, public listing, capital structure and engagement with the broader healthcare and financial markets.
Medline (Nasdaq: MDLN) will report fourth quarter and full year 2025 results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before market open, followed by a webcast and conference call at 9:30am ET / 8:30am CT.
Investors can access the live webcast and replay on Medline's Events page at ir.medline.com.
Medline (Nasdaq: MDLN) said CEO Jim Boyle and CFO Mike Drazin will present at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 3:00 PM PT.
The live presentation will stream on Medline’s investor events page at ir.medline.com, and a replay will be available on the same site for 30 days after the event.
Medline (Nasdaq: MDLN) closed an upsized initial public offering on Dec 18, 2025, selling 248,439,654 shares of Class A common stock at a public offering price of $29.00 per share, including full exercise of the underwriters' option for 32,405,172 additional shares.
Medline intends to use proceeds (net of underwriting discounts) from 179,000,000 shares to repay outstanding indebtedness under its senior secured term loan facilities, and proceeds from 37,034,482 shares plus the option shares to purchase or redeem an equivalent aggregate number of outstanding equity interests from certain pre-IPO owners. Class A common stock is listed on Nasdaq Global Select Market under MDLN.
Medline (NASDAQ: MDLN) priced an upsized initial public offering of 216,034,482 shares of Class A common stock at $29.00 per share, with underwriters granted a 30-day option for up to 32,405,172 additional shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on December 17, 2025, and the offering is expected to close on December 18, 2025. Net proceeds from 179,000,000 issued shares will repay outstanding senior secured term loan indebtedness; proceeds from 37,034,482 shares (and any option shares) will be used to purchase or redeem equity from certain pre-IPO owners.
Medline (MDLN) filed a registration statement on Form S-1 with the SEC on October 28, 2025 for a proposed initial public offering of common stock. The offering is subject to market and other conditions and the registration statement must become effective before any sale.
The number of shares, price range and final terms have not been determined. If completed, Medline intends to list on the Nasdaq Global Select Market under the symbol MDLN. Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are lead bookrunning managers.
FAQ
What is the current stock price of MEDLINE (MDLN)?
What is the market cap of MEDLINE (MDLN)?
